Mathai Mammen
InvestorAdvisor at Foresite Capital
About
Mathai Mammen has advised Foresite Capital since 2019 and is Chairman and CEO of Parabilis Medicines (formerly FogPharma). He previously served on the Executive Committee of Johnson & Johnson as EVP of J&J Pharmaceuticals R&D and was senior vice president at Merck Research Laboratories, leading research across cardiovascular, metabolic, renal, oncology/immuno-oncology and immunology areas. Earlier he co-founded and led R&D at Theravance, which he built on science from his PhD at Harvard University, and spun out Innoviva and Theravance Biopharma.
Invests in
Biotech
Investments
Board seats
Parabilis Medicines
Per the firm's website.
Colleagues at Foresite Capital
Alex M. Azar II
Advisor at Foresite Capital
Alisa Mall
Partner at Foresite Capital
Amelia Stoj
CCO and Assistant General Counsel at Foresite Capital
Cindy Xiong
Investor at Foresite Capital
Collin Yang-Wong
Principal at Foresite Capital
Cynthia Carpenter
Executive Associate at Foresite Capital
Darren Haggerty
Operations Investment Analyst at Foresite Capital
Deepak Atri
Principal at Foresite Capital
Frequently asked questions
- Who is Mathai Mammen?
- Mathai Mammen has advised Foresite Capital since 2019 and is Chairman and CEO of Parabilis Medicines (formerly FogPharma). He previously served on the Executive Committee of Johnson & Johnson as EVP of J&J Pharmaceuticals R&D and was senior vice president at Merck Research Laboratories, leading research across cardiovascular, metabolic, renal, oncology/immuno-oncology and immunology areas. Earlier he co-founded and led R&D at Theravance, which he built on science from his PhD at Harvard University, and spun out Innoviva and Theravance Biopharma.
- Where does Mathai Mammen work?
- Mathai Mammen is Advisor at Foresite Capital.
- What does Mathai Mammen invest in?
- Mathai Mammen invests in Biotech.
- What boards does Mathai Mammen sit on?
- Mathai Mammen holds tracked board seats at Parabilis Medicines.